Stockscreener 앱 받기
7.39
1.51%
0.11
시간 외 거래:
7.86
0.47
+6.36%
Climb Bio Inc 주식(CLYM)의 최신 뉴스
Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis
Wedbush Begins Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
Wedbush Initiates Climb Bio at Outperform With $12 Price Target - marketscreener.com
Wedbush initiates Climb Bio stock with Outperform rating - Investing.com
Climb 2025 10-K: $0 Revenue, $(0.88) EPS and $59.9M Net Loss - TradingView
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Aug PostEarnings: Does Climb Bio Inc offer margin of safetyJuly 2025 Highlights & Detailed Earnings Play Alerts - baoquankhu1.vn
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell Alert: Stephen Thomas Sells 50,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference - MarketBeat
Climb Bio (CLYM) Price Target Increased by 20.30% to 11.66 - Nasdaq
Proposed 50,000-share sale by CLYM broker (CLYM) - Stock Titan
CLYM: Multiple clinical readouts expected in 2024 for antibody therapies in PMN, ITP, and IgAN - TradingView
CLYM: Five clinical data readouts expected in 2024, with cash runway secured into 2028 - TradingView
Aug Update: What is Fresh Del Monte Produce Incs 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
CLYM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Climb Bio’s Stock Run Puts All Eyes On 2026 Trial Data - Finimize
Klein Hersh Recruits Chief Medical Officer for Zag Bio - Hunt Scanlon Media
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Surprises Report: Is Climb Bio Inc a stock for growth or value investorsPortfolio Performance Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Climb Bio (CLYM) director sells 100,000 shares in planned trades - Stock Titan
What’s the analyst consensus on Climb Bio Inc.Earnings Beat & Verified Short-Term Trading Plans - mfd.ru
This Taiwan Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit - MarketBeat
Piper Sandler initiates Climb Bio stock with Overweight rating, $23 target - Investing.com Canada
CLYM: Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress - TradingView
CLYM (NASDAQ: CLYM) shareholder files to sell 100,000 shares - Stock Titan
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Sahm
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Climb Bio to Present at Upcoming Investor Conferences - The Manila Times
Top High Flyer Healthcare Stocks Revealed - Intellectia AI
Cheap high flyer healthcare stockshigh momentum and low valuation (CLYM:NASDAQ) - Seeking Alpha
Activity Recap: Can Barings BDC Inc weather a recessionPortfolio Update Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Day Trade: Can Climb Bio Inc sustain its profitabilityPortfolio Performance Report & Accurate Trade Setup Notifications - baoquankhu1.vn
Tech Rally: Will Vishay Precision Group Inc announce a stock split2025 Big Picture & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Macro: Can Climb Bio Inc outperform in the next rallyLayoff News & Daily Chart Pattern Signals - baoquankhu1.vn
Zag Bio Appoints Jan Hillson, M.D., as Chief Medical Officer - Business Wire
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
Ten new option listings and two option delistings on January 22nd - TipRanks
HubSpot, Inc. (HUBS) Stock Analysis: Can It Climb 86.84% To Meet Analysts' Targets? - directorstalkinterviews.com
Climb Bio, Inc. (NASDAQ:CLYM) Short Interest Update - MarketBeat
ImmunityBio shares climb as bladder cancer trial nears full enrollment, BLA submission expected by year end - Seeking Alpha
ImmunityBio shares climb 3% premarket after company's prelim quarterly revenue exceeds estimates - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail
Resistance Check: How Climb Bio Inc stock benefits from tech adoption2025 Bull vs Bear & Long-Term Growth Portfolio Plans - Bộ Nội Vụ
Patterns Watch: How Climb Bio Inc stock benefits from tech adoption2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Bộ Nội Vụ
Winners Losers: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - Bộ Nội Vụ
Bull Bear: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 Chart Watch & High Conviction Buy Zone Picks - Bộ Nội Vụ
Laser Focus WorldClimb Bio to Present at Upcoming September 2025 Investor Conferences - FinancialContent
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
3.69%
0.68%
자본화:
|
볼륨(24시간):